SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ken Iwata, Tasuku Mashiba, Toshiaki Hitora, Yoshiki Yamagami, Tetsuji Yamamoto, A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy, Bone, 2014, 64, 183

    CrossRef

  2. 2
    Joseph Borrelli, Joseph Lane, Susan Bukata, Kenneth A. Egol, Richelle Takemoto, Gerard Slobogean, Saam Morshed, Atypical Femur Fractures, Journal of Orthopaedic Trauma, 2014, 28, S36

    CrossRef

  3. 3
    Jie Liu, Hong-xin Zhang, Xiong-xiong Lu, Jia-jia Hu, Lian-fu Deng, Bisphosphonates and Risk of Subtrochanteric, Femoral Shaft, and Atypical Femur Fracture: Sensitivity and Trim and Fill Studies, Genetic Testing and Molecular Biomarkers, 2014, 18, 2, 117

    CrossRef

  4. 4
    Silvina Andrea Soto, Angelina Chiappe Barbará, Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases, Journal of Equine Veterinary Science, 2014, 34, 6, 727

    CrossRef

  5. 5
    A. M. Pabst, T. Ziebart, M. Ackermann, M. A. Konerding, C. Walter, Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay, Clinical Oral Investigations, 2014, 18, 3, 1015

    CrossRef

  6. 6
    Ryan D Ross, Lindsey H Edwards, Alvin S Acerbo, Michael S Ominsky, Amarjit S Virdi, Kotaro Sena, Lisa M Miller, D Rick Sumner, Bone Matrix Quality After Sclerostin Antibody Treatment, Journal of Bone and Mineral Research, 2014, 29, 7
  7. 7
    Hélder Fonseca, Daniel Moreira-Gonçalves, Hans-Joachim Appell Coriolano, José Alberto Duarte, Bone Quality: The Determinants of Bone Strength and Fragility, Sports Medicine, 2014, 44, 1, 37

    CrossRef

  8. 8
    Adeline H. Ng, Thomas L. Willett, Benjamin A. Alman, Marc D. Grynpas, Development, validation and characterization of a novel mouse model of Adynamic Bone Disease (ABD), Bone, 2014, 68, 57

    CrossRef

  9. 9
    K. M. Kim, W. Park, S. Y. Oh, H.-J. Kim, W. Nam, S.-K. Lim, Y. Rhee, I. H. Cha, Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw, Osteoporosis International, 2014, 25, 5, 1625

    CrossRef

  10. 10
    Sarah K. Amugongo, Wei Yao, Junjing Jia, Weiwei Dai, Yu-An E. Lay, Li Jiang, Danielle Harvey, Elizabeth A. Zimmermann, Eric Schaible, Neil Dave, Robert O. Ritchie, Donald B. Kimmel, Nancy E. Lane, Effect of sequential treatments with alendronate, parathyroid hormone (1–34) and raloxifene on cortical bone mass and strength in ovariectomized rats, Bone, 2014, 67, 257

    CrossRef

  11. 11
    Kenneth A. Egol, Ji Hae Park, Zehava Sadka Rosenberg, Valerie Peck, Nirmal C. Tejwani, Healing Delayed But Generally Reliable After Bisphosphonate-associated Complete Femur Fractures Treated with IM Nails, Clinical Orthopaedics and Related Research®, 2014, 472, 9, 2728

    CrossRef

  12. 12
    J. J. Brady, R. K. Crowley, B. F. Murray, M. T. Kilbane, M. O’Keane, M. J. McKenna, Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis, Irish Journal of Medical Science, 2014, 183, 1, 47

    CrossRef

  13. 13
    Efstathios G. Ballas, Andreas F. Mavrogenis, Eirineos Karamanis, Zinon T. Kokkalis, Evanthia Mitsiokapa, Demetrios Koulalis, Demetrios Mastrokalos, Panayiotis J. Papagelopoulos, Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases, European Journal of Orthopaedic Surgery & Traumatology, 2014,

    CrossRef

  14. 14
    Astrid D. Bakker, Vincent Everts, Osteocytes and Osteoclasts, a Relationship Under Strain, Clinical Reviews in Bone and Mineral Metabolism, 2014, 12, 1, 14

    CrossRef

  15. 15
    Tae-Geon Kwon, Chung-O Lee, Jin-Woo Park, So-Young Choi, Girdhari Rijal, Hong-In Shin, Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment, Clinical Oral Implants Research, 2014, 25, 5
  16. 16
    R. Jiajue, Y. Jiang, O. Wang, M. Li, X. Xing, L. Cui, J. Yin, L. Xu, W. Xia, Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus, Osteoporosis International, 2014, 25, 8, 1999

    CrossRef

  17. 17
    David P. Taormina, Alejandro I. Marcano, Raj Karia, Kenneth A. Egol, Nirmal C. Tejwani, Symptomatic atypical femoral fractures are related to underlying hip geometry, Bone, 2014, 63, 1

    CrossRef

  18. 18
    Susan Y. Smith, Jacquelin Jolette, Luc Chouinard, Barry S. Komm, The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey, Journal of Bone and Mineral Metabolism, 2014,

    CrossRef

  19. 19
    Yoshitomo Saita, Muneaki Ishijima, Atsuhiko Mogami, Mitsuaki Kubota, Tomonori Baba, Takefumi Kaketa, Masashi Nagao, Yuko Sakamoto, Kensuke Sakai, Yasuhiro Homma, Rui Kato, Nana Nagura, Kei Miyagawa, Tomoki Wada, Lizu Liu, Joe Matsuoka, Osamu Obayashi, Katsuo Shitoto, Masahiko Nozawa, Hajime Kajihara, Hogaku Gen, Kazuo Kaneko, The incidence of and risk factors for developing atypical femoral fractures in Japan, Journal of Bone and Mineral Metabolism, 2014,

    CrossRef

  20. 20
    Devendra Bajaj, Joseph R. Geissler, Matthew R. Allen, David B. Burr, J.C. Fritton, The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate, Bone, 2014, 64, 57

    CrossRef

  21. 21
    Susi Zara, Marianna De Colli, Viviana di Giacomo, Vincenzo Luca Zizzari, Chiara Di Nisio, Umberto Di Tore, Vincenzo Salini, Marialucia Gallorini, Stefano Tetè, Amelia Cataldi, Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts, Clinical Oral Investigations, 2014,

    CrossRef

  22. 22
    Clifford B. Jones, Atypical Femoral Fractures: An Orthopaedic Surgeon’s Perspective, Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 2, 91

    CrossRef

  23. 23
    Jungyu Moon, Nitin Bither, Taehun Lee, Atypical forearm fractures associated with long-term use of bisphosphonate, Archives of Orthopaedic and Trauma Surgery, 2013, 133, 7, 889

    CrossRef

  24. 24
    Lyne Bissonnette, Pierre-Marc April, Réjean Dumais, Gilles Boire, Sophie Roux, Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: A case report, Bone, 2013, 56, 2, 406

    CrossRef

  25. 25
    Anas Saleh, Vishal V. Hegde, Anish G. Potty, Joseph M. Lane, Bisphosphonate Therapy and Atypical Fractures, Orthopedic Clinics of North America, 2013, 44, 2, 137

    CrossRef

  26. 26
    Eric R. Smith, Matthew R. Allen, Bisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependent, Journal of Orthopaedic Research, 2013, 31, 8
  27. 27
    Lydia Gedmintas, Daniel H Solomon, Seoyoung C Kim, Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis, Journal of Bone and Mineral Research, 2013, 28, 8
  28. 28
    Yoshiki Yamagami, Tasuku Mashiba, Ken Iwata, Makoto Tanaka, Kazutoshi Nozaki, Tetsuji Yamamoto, Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys, Bone, 2013, 54, 1, 1

    CrossRef

  29. 29
    Jörg Schilcher, Epidemiology, radiology and histology of atypical femoral fractures, Acta Orthopaedica, 2013, 84, S352, 1

    CrossRef

  30. 30
    Samuel Gourion-Arsiquaud, Lyudmilla Lukashova, Jon Power, Nigel Loveridge, Jonathan Reeve, Adele L Boskey, Fourier transform infrared imaging of femoral neck bone: Reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls, Journal of Bone and Mineral Research, 2013, 28, 1
  31. 31
    Cem Copuroglu, Giorgio M. Calori, Peter V. Giannoudis, Fracture non-union: Who is at risk?, Injury, 2013, 44, 11, 1379

    CrossRef

  32. 32
    Sukumaran Anil, Reghunathan S. Preethanath, Hani S. AlMoharib, Kavitha P. Kamath, Pradeep S. Anand, Impact of Osteoporosis and Its Treatment on Oral Health, The American Journal of the Medical Sciences, 2013, 346, 5, 396

    CrossRef

  33. 33
    Ziheng Wu, Anthony J. LaNeve, Glen L. Niebur, In vivo microdamage is an indicator of susceptibility to initiation and propagation of microdamage in human femoral trabecular bone, Bone, 2013, 55, 1, 208

    CrossRef

  34. 34
    Mathieu Gunepin, Florence Derache, Olivier Cathelinaud, Jean-Pierre De Jaureguibery, Jean Sébastien Bladé, Olivier Gisserot, Jean-Jacques Risso, Jean-Eric Blatteau, Michel Hugon, Benoît Bédrune, Didier Rivière, Intérêt de l’oxygénothérapie hyperbare dans la prévention et le traitement des ostéonécroses des maxillaires dues aux bisphosphonates, Médecine Buccale Chirurgie Buccale, 2013, 19, 2, 91

    CrossRef

  35. 35
    Gulcan Coskun Akar, Candan Efeoglu, Alper Alp, Kutsi Koseoglu, Haluk Erol, Yavuz Yenicerioglu, Harun Akar, Malnutrition due to bisphosphonate-related osteonecrosis of the jaw in a chronic dialysis patient: case report, Renal Failure, 2013, 35, 7, 1008

    CrossRef

  36. 36
    Mathieu Gunepin, Florence Derache, Jean-Pierre De Jaureguibery, Jean-Sébastien Bladé, Olivier Gisserot, Olivier Cathelinaud, Benoît Bédrune, Didier Rivière, Ostéonécroses des maxillaires dues aux bisphosphonates administrés par voie intraveineuse : incidence et facteurs de risque, Médecine Buccale Chirurgie Buccale, 2013, 19, 1, 21

    CrossRef

  37. 37
    Benjamin P Sinder, Mary M Eddy, Michael S Ominsky, Michelle S Caird, Joan C Marini, Kenneth M Kozloff, Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta, Journal of Bone and Mineral Research, 2013, 28, 1
  38. 38
    Tianyi D. Luo, Matthew R. Allen, Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness, Bone, 2013, 56, 1, 199

    CrossRef

  39. 39
    Kenneth A. Egol, Ji H. Park, Colin Prensky, Zehava S. Rosenberg, Valerie Peck, Nirmal C. Tejwani, Surgical Treatment Improves Clinical and Functional Outcomes for Patients Who Sustain Incomplete Bisphosphonate-Related Femur Fractures, Journal of Orthopaedic Trauma, 2013, 27, 6, 331

    CrossRef

  40. 40
    Cherie Ying Chiang, Roger M.D. Zebaze, Ali Ghasem-Zadeh, Sandra Iuliano-Burns, Andrew Hardidge, Ego Seeman, Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy, Bone, 2013, 52, 1, 360

    CrossRef

  41. 41
    Sun-Don Kim, Ha-Neui Kim, Jong-Ho Lee, Won Jong Jin, Soon Jung Hwang, Hong-Hee Kim, Hyunil Ha, Zang Hee Lee, Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice, Biochemical Pharmacology, 2013, 86, 6, 782

    CrossRef

  42. 42
    Hua Zhou, David W. Dempster, Osteoporosis, 2013,

    CrossRef

  43. 43
    Lamya Karim, Amira I. Hussein, Elise F. Morgan, Mary L. Bouxsein, Osteoporosis, 2013,

    CrossRef

  44. 44
    Paul Kostenuik, Osteoporosis, 2013,

    CrossRef

  45. 45
    Robert Marcus, David W. Dempster, Mary L. Bouxsein, Osteoporosis, 2013,

    CrossRef

  46. 46
    Elizabeth Shane, Sundeep Khosla, David Burr, Osteoporosis, 2013,

    CrossRef

  47. 47
    Won-Ju Jeong, Sang-Bong Na, Hwan-Seong Cho, Joon-Woo Kim, Il-Hyung Park, An Atypical Subtrochanteric Femoral Fracture in a Patient with Multiple Myeloma Received Zoledronic Acid: A Case Report, The Journal of the Korean Bone and Joint Tumor Society, 2012, 18, 2, 99

    CrossRef

  48. 48
    Marcus Zulian Teixeira, Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude, Homeopathy, 2012, 101, 4, 231

    CrossRef

  49. 49
    Frieda Feldman, Atypical diaphyseal femoral fractures—new aspects, Skeletal Radiology, 2012, 41, 1, 75

    CrossRef

  50. 50
    C. Jerome, M. Missbach, R. Gamse, Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys, Osteoporosis International, 2012, 23, 1, 339

    CrossRef

  51. 51
    Carmen M. Romero Barco, Sara Manrique Arija, Manuel Rodríguez Pérez, Biochemical Markers in Osteoporosis: Usefulness in Clinical Practice, Reumatología Clínica (English Edition), 2012, 8, 3, 149

    CrossRef

  52. 52
    Sarah G. Fitzpatrick, Mary F. Stavropoulos, Leah M. Bowers, Ashley N. Neuman, David W. Hinkson, James G. Green, Indraneel Bhattacharyya, Donald M. Cohen, Bisphosphonate-Related Osteonecrosis of Jaws in 3 Osteoporotic Patients With History of Oral Bisphosphonate Use Treated With Single Yearly Zoledronic Acid Infusion, Journal of Oral and Maxillofacial Surgery, 2012, 70, 2, 325

    CrossRef

  53. 53
    Dima L. Diab, Nelson B. Watts, Bisphosphonates in the Treatment of Osteoporosis, Endocrinology and Metabolism Clinics of North America, 2012, 41, 3, 487

    CrossRef

  54. 54
    Yohann Bala, Baptiste Depalle, Delphine Farlay, Thierry Douillard, Sylvain Meille, Helene Follet, Roland Chapurlat, Jérôme Chevalier, Georges Boivin, Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization, Journal of Bone and Mineral Research, 2012, 27, 4
  55. 55
    Sang-Bong Ko, Sang-Wook Lee, Chang-Min Park, Sang-Hwa Lee, Clinical Analysis of Femur Shaft Insufficiency Fractures, Clinics in Orthopedic Surgery, 2012, 4, 3, 227

    CrossRef

  56. 56
    Andreas Seraphim, Nawfal Al-Hadithy, Simon C. Mordecai, Shafic Al-Nammari, Do bisphosphonates cause femoral insufficiency fractures?, Journal of Orthopaedics and Traumatology, 2012, 13, 4, 171

    CrossRef

  57. 57
    Ki Hyoung Koo, Jae Hyup Lee, Bong-Soon Chang, Choon-Ki Lee, Effects of Alendronate on Lumbar Posterolateral Fusion Using Hydroxyapatite in Rabbits, Artificial Organs, 2012, 36, 12
  58. 58
    Yoshitomo Kajino, Tamon Kabata, Koji Watanabe, Hiroyuki Tsuchiya, Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy, Journal of Orthopaedic Science, 2012, 17, 3, 313

    CrossRef

  59. 59
    Mathieu S. Davis, Bethany L. Kovacic, Joan C. Marini, Albert J. Shih, Kenneth M. Kozloff, Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta, Bone, 2012, 50, 3, 784

    CrossRef

  60. 60
    Jeffrey R. Curtis, Monika M. Safford, Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions, Drugs & Aging, 2012, 29, 7, 549

    CrossRef

  61. 61
    V. J. V. Vigorita, J. S. Silver, E. O. E. Eisemon, Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report, Skeletal Radiology, 2012, 41, 7, 861

    CrossRef

  62. 62
    Joan Otomo-Corgel, Osteoporosis and osteopenia: implications for periodontal and implant therapy, Periodontology 2000, 2012, 59, 1
  63. 63
    Duarte Nuno Alegre, Costa Ribeiro, Carlos Sousa, João Correia, Luís Silva, Luís de Almeida, Possible benefits of strontium ranelate in complicated long bone fractures, Rheumatology International, 2012, 32, 2, 439

    CrossRef

  64. 64
    Hsuan-Ti Huang, Lin Kang, Peng-Ju Huang, Yin-Chih Fu, Sung-Yen Lin, Chih-Hsin Hsieh, Jian-Chih Chen, Yuh-Min Cheng, Chung-Hwan Chen, Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman, Menopause: The Journal of The North American Menopause Society, 2012, 19, 12, 1360

    CrossRef

  65. 65
    Aasis Unnanuntana, Kashif Ashfaq, Quang V. Ton, John P. Kleimeyer, Joseph M. Lane, The Effect of Long-term Alendronate Treatment on Cortical Thickness of the Proximal Femur, Clinical Orthopaedics and Related Research®, 2012, 470, 1, 291

    CrossRef

  66. 66
    Lamya Karim, Mary L Bouxsein, The relative influence of damage versus density on trabecular bone mechanical behavior, IBMS BoneKEy, 2012, 9,

    CrossRef

  67. 67
    Chun Wang, Hao Zhang, Jin-Wei He, Jie-Mei Gu, Wei-Wei Hu, Yun-Qiu Hu, Miao Li, Yu-Juan Liu, Wen-Zhen Fu, Hua Yue, Yao-Hua Ke, Zhen-Lin Zhang, The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families, Journal of Bone and Mineral Metabolism, 2012, 30, 3, 338

    CrossRef

  68. 68
    J. O. Green, T. Diab, M. R. Allen, B. Vidakovic, D. B. Burr, R. E. Guldberg, Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year, Osteoporosis International, 2012, 23, 9, 2313

    CrossRef

  69. 69
    C. Jerome, M. Missbach, R. Gamse, Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys, Osteoporosis International, 2011, 22, 12, 3001

    CrossRef

  70. 70
    P. Habibovic, J.E. Barralet, Bioinorganics and biomaterials: Bone repair, Acta Biomaterialia, 2011, 7, 8, 3013

    CrossRef

  71. 71
    Matthew R. Allen, David B. Burr, Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know, Bone, 2011, 49, 1, 56

    CrossRef

  72. 72
    Kimberly McKenzie, J. Dennis Bobyn, Jacintha Roberts, Dorota Karabasz, Michael Tanzer, Bisphosphonate Remains Highly Localized After Elution From Porous Implants, Clinical Orthopaedics and Related Research®, 2011, 469, 2, 514

    CrossRef

  73. 73
    Thomas Ziebart, Andreas Pabst, Marcus Oliver Klein, Peer Kämmerer, Leonie Gauss, Dan Brüllmann, Bilal Al-Nawas, Christian Walter, Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro, Clinical Oral Investigations, 2011, 15, 1, 105

    CrossRef

  74. 74
    R. Graham G. Russell, Bisphosphonates: The first 40years, Bone, 2011, 49, 1, 2

    CrossRef

  75. 75
    Shunsuke Goto, Hideki Fujii, Keiji Kono, Kentaro Nakai, Yasuhiro Hamada, Hideyuki Yamato, Masami Shinohara, Riko Kitazawa, Sohei Kitazawa, Shinichi Nishi, Masafumi Fukagawa, Carvedilol Ameliorates Low-Turnover Bone Disease in Non-Obese Type 2 Diabetes, American Journal of Nephrology, 2011, 34, 3, 281

    CrossRef

  76. 76
    Roland Baron, Serge Ferrari, R. Graham G. Russell, Denosumab and bisphosphonates: Different mechanisms of action and effects, Bone, 2011, 48, 4, 677

    CrossRef

  77. 77
    Kaiya Osugi, Shigeki Miwa, Shinobu Marukawa, Kouhei Marukawa, Yoshiharu Kawaguchi, Shinichi Nakato, Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy – 3 more cases, Acta Orthopaedica, 2011, 82, 1, 112

    CrossRef

  78. 78
    Marie K. Reumann, Olga Strachna, Lyudmila Lukashova, Kostas Verdelis, Eve Donnelly, Adele L. Boskey, Philipp Mayer-Kuckuk, Early Growth Response Gene 1 Regulates Bone Properties in Mice, Calcified Tissue International, 2011, 89, 1, 1

    CrossRef

  79. 79
    Orlaith Brennan, Oran D. Kennedy, T. Clive Lee, Susan M. Rackard, Fergal J. O'Brien, Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis, Journal of Orthopaedic Research, 2011, 29, 3
  80. 80
    Christian M. Girgis, Markus J. Seibel, Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures, Bone, 2011, 48, 5, 963

    CrossRef

  81. 81
    Talal M Zahid, Bing-Yan Wang, Robert E Cohen, Influence of Bisphosphonates on Alveolar Bone Loss Around Osseointegrated Implants, Journal of Oral Implantology, 2011, 37, 3, 335

    CrossRef

  82. 82
    Carmen M. Romero Barco, Sara Manrique Arija, Manuel Rodríguez Pérez, Marcadores bioquímicos en osteoporosis. Utilidad en la práctica clínica, Reumatología Clínica, 2011,

    CrossRef

  83. 83
    Crystal K. Tjhia, Clarita V. Odvina, D. Sudhaker Rao, Susan M. Stover, Xiang Wang, David P. Fyhrie, Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects, Bone, 2011, 49, 6, 1279

    CrossRef

  84. 84
    Joong Kyong Ahn, Jaejoon Lee, Hoon-Suk Cha, Eun-Mi Koh, Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy, Rheumatology International, 2011, 31, 7, 973

    CrossRef

  85. 85
    Michael B. Banffy, Mark S. Vrahas, John E. Ready, John A. Abraham, Nonoperative versus Prophylactic Treatment of Bisphosphonate-associated Femoral Stress Fractures, Clinical Orthopaedics and Related Research®, 2011, 469, 7, 2028

    CrossRef

  86. 86
    Enrique Casado Burgos, Nuevos datos sobre el tratamiento con bisfosfonatos: ¿son aconsejables unas vacaciones terapéuticas?, Reumatología Clínica, 2011, 7, 28

    CrossRef

  87. 87
    E. Michael Lewiecki, John P. Bilezikian, Sundeep Khosla, Robert Marcus, Michael R. McClung, Paul D. Miller, Nelson B. Watts, Michael Maricic, Osteoporosis Update From the 2010 Santa Fe Bone Symposium, Journal of Clinical Densitometry, 2011, 14, 1, 1

    CrossRef

  88. 88
    J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw, Osteoporosis International, 2011, 22, 12, 2951

    CrossRef

  89. 89
    Toshihiro Sugiyama, Lee B. Meakin, Gabriel L. Galea, Brendan F. Jackson, Lance E. Lanyon, Frank H. Ebetino, R. Graham G. Russell, Joanna S. Price, Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice, Bone, 2011, 49, 1, 133

    CrossRef

  90. 90
    Jacqueline G. Garrison, Joshua A. Gargac, Glen L. Niebur, Shear strength and toughness of trabecular bone are more sensitive to density than damage, Journal of Biomechanics, 2011, 44, 16, 2747

    CrossRef

  91. 91
    Robert R. Recker, Laura Armas, The Effect of Antiresorptives on Bone Quality, Clinical Orthopaedics and Related Research®, 2011, 469, 8, 2207

    CrossRef

  92. 92
    Matthew R. Allen, The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing, Odontology, 2011, 99, 1, 8

    CrossRef

  93. 93
    Yoram A. Weil, Gurion Rivkin, Ori Safran, Meir Liebergall, A. Joseph Foldes, The Outcome of Surgically Treated Femur Fractures Associated With Long-Term Bisphosphonate Use, The Journal of Trauma: Injury, Infection, and Critical Care, 2011, 71, 1, 186

    CrossRef

  94. 94
    Socrates E. Papapoulos, Use of bisphosphonates in the management of postmenopausal osteoporosis, Annals of the New York Academy of Sciences, 2011, 1218, 1
  95. 95
    Amanda Agnew, John Bolte, Bone Histology, 2011,

    CrossRef

  96. 96
    Nigel D. Toussaint, Grahame J. Elder, Peter G. Kerr, A Rational Guide to Reducing Fracture Risk in Dialysis Patients, Seminars in Dialysis, 2010, 23, 1
  97. 97
    Joel A. Horning, John Czajka, Richard L. Uhl, David J. Hak, Philip F. Stahel, Atypical Diaphyseal Femur Fractures in Patients with Prolonged Administration of Bisphosphonate Medication for Osteoporosis, Orthopedics, 2010, 33, 12, 902

    CrossRef

  98. 98
    Michael D. Breglia, John D. Carter, Atypical Insufficiency Fracture of the Tibia Associated With Long-Term Bisphosphonate Therapy, JCR: Journal of Clinical Rheumatology, 2010, 16, 2, 76

    CrossRef

  99. You have free access to this content99
    Elizabeth Shane, David Burr, Peter R Ebeling, Bo Abrahamsen, Robert A Adler, Thomas D Brown, Angela M Cheung, Felicia Cosman, Jeffrey R Curtis, Richard Dell, David Dempster, Thomas A Einhorn, Harry K Genant, Piet Geusens, Klaus Klaushofer, Kenneth Koval, Joseph M Lane, Fergus McKiernan, Ross McKinney, Alvin Ng, Jeri Nieves, Regis O'Keefe, Socrates Papapoulos, Howe Tet Sen, Marjolein CH van der Meulen, Robert S Weinstein, Michael Whyte, Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research, Journal of Bone and Mineral Research, 2010, 25, 11
  100. 100
    Samuel Gourion-Arsiquaud, Matthew R. Allen, David B. Burr, Deepak Vashishth, Simon Y. Tang, Adele L. Boskey, Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity, Bone, 2010, 46, 3, 666

    CrossRef

  101. 101
    N. Napoli, D. Novack, R. Armamento-Villareal, Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies, Osteoporosis International, 2010, 21, 4, 705

    CrossRef

  102. 102
    Anthony Feher, Andrew Koivunemi, Mark Koivunemi, Robyn K. Fuchs, David B. Burr, Roger J. Phipps, Susan Reinwald, Matthew R. Allen, Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading, Bone, 2010, 46, 1, 203

    CrossRef

  103. 103
    Ego Seeman, Bone morphology in response to alendronate as seen by high-resolution computed tomography: Through a glass darkly, Journal of Bone and Mineral Research, 2010, 25, 12
  104. 104
    Matthew R Allen, Daniel J Kubek, David B Burr, Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs, Journal of Bone and Mineral Research, 2010, 25, 1
  105. 105
    Marcelo Coelho Goiato, Daniela Micheline dos Santos, Bruna Carolina Santos Rondon, Amália Moreno, Gabriella Trunkcle Baptista, Fellippo Ramos Verri, Stefan Fiuza de Carvalho Dekon, Care Required When Using Bisphosphonates in Dental Surgical Practice, Journal of Craniofacial Surgery, 2010, 21, 6, 1966

    CrossRef

  106. 106
    K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, A. C. W. Zannettino, Dysregulation of bone remodeling by imatinib mesylate, Blood, 2010, 115, 4, 766

    CrossRef

  107. 107
    Sun Im, Seong-Hoon Lim, Jong-In Lee, Young-Jin Ko, Joo Hyun Park, Bo-Young Hong, Geun-Young Park, Effective Dosage and Administration Schedule of Oral Alendronate for Non-nociceptive Symptoms in Rats with Chronic Constriction Injury, Journal of Korean Medical Science, 2010, 25, 6, 938

    CrossRef

  108. 108
    Hiroto Nakayama, Kazuo Takakuda, Hiroko N. Matsumoto, Atsushi Miyata, Otto Baba, Makoto J. Tabata, Tatsuo Ushiki, Tsuyoshi Oda, Marc D. McKee, Yoshiro Takano, Effects of Altered Bone Remodeling and Retention of Cement Lines on Bone Quality in Osteopetrotic Aged c-Src-Deficient Mice, Calcified Tissue International, 2010, 86, 2, 172

    CrossRef

  109. 109
    Hiroshi Sasaki, Naohisa Miyakoshi, Yuji Kasukawa, Shigeto Maekawa, Hideaki Noguchi, Keji Kamo, Yoichi Shimada, Effects of combination treatment with alendronate and vitamin K2 on bone mineral density and strength in ovariectomized mice, Journal of Bone and Mineral Metabolism, 2010, 28, 4, 403

    CrossRef

  110. 110
    Joseph D. Isaacs, Louis Shidiak, Ian A. Harris, Zoltan L. Szomor, Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy, Clinical Orthopaedics and Related Research®, 2010, 468, 12, 3384

    CrossRef

  111. 111
    Mohammad Shahnazari, Wei Yao, WeiWei Dai, Bob Wang, Sophi S. Ionova-Martin, Robert O. Ritchie, Daniel Heeren, Andrew J. Burghardt, Daniel P. Nicolella, Michael G. Kimiecik, Nancy E. Lane, Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats, Bone, 2010, 46, 5, 1267

    CrossRef

  112. 112
    C. Walter, M. O. Klein, A. Pabst, B. Al-Nawas, H. Duschner, T. Ziebart, Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells, Clinical Oral Investigations, 2010, 14, 1, 35

    CrossRef

  113. 113
    Kyu-Hyun Yang, Si-Young Park, Sang-Won Park, Soon-Hyuck Lee, Seung-Beom Han, Woong-Kyo Jung, Suk-Jin Kim, Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate, Journal of Bone and Mineral Metabolism, 2010, 28, 6, 713

    CrossRef

  114. 114
    Yong-Chan Ha, Myung-Rae Cho, Ki Hong Park, Shin-Yoon Kim, Kyung-Hoi Koo, Is Surgery Necessary for Femoral Insufficiency Fractures after Long-term Bisphosphonate Therapy?, Clinical Orthopaedics and Related Research®, 2010, 468, 12, 3393

    CrossRef

  115. 115
    Ming Ding, Microarchitectural adaptations in aging and osteoarthrotic subchondral bone issues, Acta Orthopaedica, 2010, 81, s340, 1

    CrossRef

  116. 116
    Philippe Lesclous, Simon Abi Najm, Jean-Pierre Carrel, Brigitte Baroukh, Tommaso Lombardi, Jean-Pierre Willi, René Rizzoli, Jean-Louis Saffar, Jacky Samson, Reply to “Fatigue in bone: A novel phenomenon attributable to bisphosphonate use”, Bone, 2010, 46, 2, 557

    CrossRef

  117. 117
    Kate Vandyke, Andrea L Dewar, Peter Diamond, Stephen Fitter, Christopher G Schultz, Natalie A Sims, Andrew CW Zannettino, The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo, Journal of Bone and Mineral Research, 2010, 25, 8
  118. 118
    Clarita V. Odvina, Shiri Levy, Sudhir Rao, Joseph E. Zerwekh, D. S. Rao, Unusual mid-shaft fractures during long-term bisphosphonate therapy, Clinical Endocrinology, 2010, 72, 2
  119. 119
    B. A. Lenart, A. S. Neviaser, S. Lyman, C. C. Chang, F. Edobor-Osula, B. Steele, M. C. H. Meulen, D. G. Lorich, J. M. Lane, Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study, Osteoporosis International, 2009, 20, 8, 1353

    CrossRef

  120. 120
    Cemal Kazimoglu, Hasan Karapinar, Muhittin Sener, Attila Bozkurt, Bilateral Stress Fractures of the Distal Fibula in a Woman with Osteoporosis, Journal of the American Podiatric Medical Association, 2009, 99, 1, 61

    CrossRef

  121. 121
    Allauddin Siddiqi, Alan G.T. Payne, Sobia Zafar, Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2009, 108, 3, e1

    CrossRef

  122. 122
    Robin N. Goytia, Andrew Salama, Harpal S. Khanuja, Bisphosphonates and Osteonecrosis: Potential Treatment or Serious Complication?, Orthopedic Clinics of North America, 2009, 40, 2, 223

    CrossRef

  123. 123
    R. D. Chapurlat, Bone microdamage, Osteoporosis International, 2009, 20, 6, 1033

    CrossRef

  124. 124
    R. D. Chapurlat, P. D. Delmas, Bone microdamage: a clinical perspective, Osteoporosis International, 2009, 20, 8, 1299

    CrossRef

  125. 125
    Reina Armamento-Villareal, Nicola Napoli, Kathryn Diemer, Marcus Watkins, Roberto Civitelli, Steven Teitelbaum, Deborah Novack, Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series, Calcified Tissue International, 2009, 85, 1, 37

    CrossRef

  126. 126
    R. Civitelli, R. Armamento-Villareal, N. Napoli, Bone turnover markers: understanding their value in clinical trials and clinical practice, Osteoporosis International, 2009, 20, 6, 843

    CrossRef

  127. 127
    S. Y. Tang, M. R. Allen, R. Phipps, D. B. Burr, D. Vashishth, Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate, Osteoporosis International, 2009, 20, 6, 887

    CrossRef

  128. 128
    Jacqueline G. Garrison, Constance L. Slaboch, Glen L. Niebur, Density and architecture have greater effects on the toughness of trabecular bone than damage, Bone, 2009, 44, 5, 924

    CrossRef

  129. 129
    J. E. M. Brouwers, M. Ruchelsman, B. v. Rietbergen, M. L. Bouxsein, Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats, Osteoporosis International, 2009, 20, 8, 1377

    CrossRef

  130. 130
    David B. Burr, Tamim Diab, Andrew Koivunemi, Mark Koivunemi, Matthew R. Allen, Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk, Journal of Orthopaedic Research, 2009, 27, 10
  131. 131
    Lian-wen Sun, Yu-bo Fan, De-yu Li, Feng Zhao, Tian Xie, Xiao Yang, Zhang-ting Gu, Evaluation of the mechanical properties of rat bone under simulated microgravity using nanoindentation, Acta Biomaterialia, 2009, 5, 9, 3506

    CrossRef

  132. 132
    Christian Walter, Bilal Al-Nawas, Andreas du Bois, Laura Buch, Philipp Harter, Knut A. Grötz, Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients, Cancer, 2009, 115, 8
  133. 133
    DB Burr, MR Allen, Mandibular necrosis in beagle dogs treated with bisphosphonates, Orthodontics & Craniofacial Research, 2009, 12, 3
  134. 134
    Anita H. Undale, Jennifer J. Westendorf, Michael J. Yaszemski, Sundeep Khosla, Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases, Mayo Clinic Proceedings, 2009, 84, 10, 893

    CrossRef

  135. 135
    Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer, Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009, Wiener Medizinische Wochenschrift, 2009, 159, S122, 1

    CrossRef

  136. 136
    Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel, Safety of Bisphosphonates in the Treatment of Osteoporosis, The American Journal of Medicine, 2009, 122, 2, S22

    CrossRef

  137. 137
    S.Y. Smith, J. Jolette, C.H. Turner, Skeletal health: primate model of postmenopausal osteoporosis, American Journal of Primatology, 2009, 71, 9
  138. 138
    Matthew R. Allen, Studying the role of microcracks in the pathophysiology of BRONJ, Clinical Oral Investigations, 2009, 13, 4, 481

    CrossRef

  139. 139
    Matthew R. Allen, David B. Burr, The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data, Journal of Oral and Maxillofacial Surgery, 2009, 67, 5, 61

    CrossRef

  140. 140
    Xiang Wang, Antonia M. Erickson, Matthew R. Allen, David B. Burr, R. Bruce Martin, Scott J. Hazelwood, Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage, Journal of Biomechanics, 2009, 42, 7, 938

    CrossRef

  141. 141
    P. Szulc, E. Seeman, Thinking inside and outside the envelopes of bone, Osteoporosis International, 2009, 20, 8, 1281

    CrossRef

  142. 142
    Ego Seeman, To stop or not to stop, that is the question, Osteoporosis International, 2009, 20, 2, 187

    CrossRef

  143. 143
    Yosuke Shima, Lars Engebretsen, Junji Iwasa, Katsuhiko Kitaoka, Katsuro Tomita, Use of bisphosphonates for the treatment of stress fractures in athletes, Knee Surgery, Sports Traumatology, Arthroscopy, 2009, 17, 5, 542

    CrossRef

  144. 144
    R.K. Fuchs, S.J. Warden, C.H. Turner, Bone Repair Biomaterials, 2009,

    CrossRef

  145. 145
    Timothy L. Norman, Tara M. Little, Yener N. Yeni, Age-related changes in porosity and mineralization and in-service damage accumulation, Journal of Biomechanics, 2008, 41, 13, 2868

    CrossRef

  146. 146
    Matthew R. Allen, Susan Reinwald, David B. Burr, Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily Treatment, Calcified Tissue International, 2008, 82, 5, 354

    CrossRef

  147. 147
    Maria-Theresa Krauth, Alexander Fügl, Reinhard Gruber, Bisphosphonat-assoziierte Osteonekrosen des Kieferknochens, Wiener klinische Wochenschrift, 2008, 120, 15-16, 467

    CrossRef

  148. 148
    M. R. Allen, E. Gineyts, D. J. Leeming, D. B. Burr, P. D. Delmas, Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra, Osteoporosis International, 2008, 19, 3, 329

    CrossRef

  149. 149
    Socrates E. Papapoulos, Bisphosphonates: how do they work?, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 5, 831

    CrossRef

  150. 150
    T. John Martin, Ego Seeman, Bone remodelling: its local regulation and the emergence of bone fragility, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 5, 701

    CrossRef

  151. 151
    Xiang Wang, Roger R. Zauel, D. Sudhaker Rao, David P. Fyhrie, Cancellous bone lamellae strongly affect microcrack propagation and apparent mechanical properties: Separation of patients with osteoporotic fracture from normal controls using a 2D nonlinear finite element method (biomechanical stereology), Bone, 2008, 42, 6, 1184

    CrossRef

  152. 152
    Greg Wernecke, Surena Namduri, Edward F. DiCarlo, Robert Schneider, Joseph Lane, Case Report of Spontaneous, Nonspinal Fractures in a Multiple Myeloma Patient on Long-term Pamidronate and Zoledronic Acid, HSS Journal, 2008, 4, 2, 123

    CrossRef

  153. 153
    J. R. Tucci, Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity — Observations in two elderly patients, Journal of Endocrinological Investigation, 2008, 31, 3, 251

    CrossRef

  154. 154
    Romain Voide, G. Harry van Lenthe, Ralph Müller, Femoral stiffness and strength critically depend on loading angle: a parametric study in a mouse-inbred strain, Biomedizinische Technik/Biomedical Engineering, 2008, 53, 3, 122

    CrossRef

  155. 155
    David B Burr, Matthew R Allen, Low Bone Turnover and Microdamage? How and Where to Assess It?, Journal of Bone and Mineral Research, 2008, 23, 7
  156. 156
    Roland D Chapurlat, Monique Arlot, Pierre D Delmas, Low Bone Turnover and Microdamage? How and Where to Assess It?, Journal of Bone and Mineral Research, 2008, 23, 7
  157. 157
    Seth M Arum, New developments surrounding the safety of bisphosphonates, Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 6, 508

    CrossRef

  158. 158
    Ippokratis Pountos, Theodora Georgouli, Taco J. Blokhuis, Hans Chistoph Pape, Peter V. Giannoudis, Pharmacological agents and impairment of fracture healing: What is the evidence?, Injury, 2008, 39, 4, 384

    CrossRef

  159. 159
    Brian L. Foster, Kevin A. Tompkins, R. Bruce Rutherford, Hai Zhang, Emily Y. Chu, Hanson Fong, Martha J. Somerman, Phosphate: Known and potential roles during development and regeneration of teeth and supporting structures, Birth Defects Research Part C: Embryo Today: Reviews, 2008, 84, 4
  160. 160
    Christian Walter, Bilal Al-Nawas, Knut A. Grötz, Christian Thomas, Joachim W. Thüroff, Viktoria Zinser, Heinold Gamm, Joachim Beck, Wilfried Wagner, Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate, European Urology, 2008, 54, 5, 1066

    CrossRef

  161. 161
    B. M. Misof, M. Bodingbauer, P. Roschger, T. Wekerle, B. Pakrah, M. Haas, A. Kainz, R. Oberbauer, F. Mühlbacher, K. Klaushofer, Short-Term Effects of High-Dose Zoledronic Acid Treatment on Bone Mineralization Density Distribution After Orthotopic Liver Transplantation, Calcified Tissue International, 2008, 83, 3, 167

    CrossRef

  162. 162
    Matthew R. Allen, David B. Burr, Skeletal Microdamage: Less About Biomechanics and More About Remodeling, Clinical Reviews in Bone and Mineral Metabolism, 2008, 6, 1-2, 24

    CrossRef

  163. 163
    Matthew R. Allen, Surface-specific Bone Formation Effects of Osteoporosis Pharmacological Treatments, Clinical Reviews in Bone and Mineral Metabolism, 2008, 6, 1-2, 62

    CrossRef

  164. 164
    Ming Ding, Carl Christian Danielsen, Ivan Hvid, The Effects of Bone Remodeling Inhibition by Alendronate on Three-Dimensional Microarchitecture of Subchondral Bone Tissues in Guinea Pig Primary Osteoarthrosis, Calcified Tissue International, 2008, 82, 1, 77

    CrossRef

  165. 165
    Jarkko Jokihaara, Ilkka H Pörsti, Peeter Kööbi, Pasi M Jolma, Jukka T Mustonen, Heikki H T Saha, Harri Sievänen, Pekka Kannus, Urszula T Iwaniec, Russell T Turner, Teppo L N Järvinen, Treatment of experimental renal osteodystrophy with pamidronate, Kidney International, 2008, 74, 3, 319

    CrossRef

  166. 166
    Elise F. Morgan, Mary L. Bouxsein, Principles of Bone Biology, 2008,

    CrossRef

  167. 167
    Ego Seeman, Principles of Bone Biology, 2008,

    CrossRef

  168. 168
    Morten A Karsdal, Thomas J Martin, Jens Bollerslev, Claus Christiansen, Kim Henriksen, Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?, Journal of Bone and Mineral Research, 2007, 22, 4
  169. 169
    Jean-Jacques Body, Bisphosphonates in Advanced Malignant Disease, Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 3, 172

    CrossRef

  170. 170
    Takafumi MAJIMA, Yasato KOMATSU, Akira SHIMATSU, Noriko SATOH, Atsushi FUKAO, Kiyoshi NINOMIYA, Tadashi MATSUMURA, Kazuwa NAKAO, Clinical Significance of 1-year Treatment with Raloxifene on Bone and Lipid Metabolism in Japanese Postmenopausal Women with Osteoporosis, Endocrine Journal, 2007, 54, 6, 855

    CrossRef

  171. 171
    JoAnn V. Pinkerton, Alan C. Dalkin, Combination therapy for treatment of osteoporosis: A review, American Journal of Obstetrics and Gynecology, 2007, 197, 6, 559

    CrossRef

  172. 172
    Jennifer G. Barrett, Susannah J. Sample, Jenna McCarthy, Vicki L. Kalscheur, Peter Muir, Laura Prokuski, Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats, Journal of Orthopaedic Research, 2007, 25, 8
  173. 173
    C. Seebach, A. Kurth, I. Marzi, Einfluss der Bisphosphonate auf die Frakturheilung, Der Orthopäde, 2007, 36, 2, 136

    CrossRef

  174. 174
    Takeshi Manabe, Satoshi Mori, Tasuku Mashiba, Yoshio Kaji, Ken Iwata, Satoshi Komatsubara, Azusa Seki, Yong-Xin Sun, Tetsuji Yamamoto, Human parathyroid hormone (1–34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys, Bone, 2007, 40, 6, 1475

    CrossRef

  175. 175
    Paul A. Fugazzotto, W. Scott Lightfoot, Robert Jaffin, Ashkay Kumar, Implant Placement With or Without Simultaneous Tooth Extraction in Patients Taking Oral Bisphosphonates: Postoperative Healing, Early Follow-Up, and the Incidence of Complications in Two Private Practices, Journal of Periodontology, 2007, 78, 9, 1664

    CrossRef

  176. 176
    Hatice Altundal, Hakan Sayrak, Ertuğrul Yurtsever, Kamil Göker, Inhibitory Effect of Alendronate on Bone Resorption of Autogenous Free Bone Grafts in Rats, Journal of Oral and Maxillofacial Surgery, 2007, 65, 3, 508

    CrossRef

  177. 177
    E. Seeman, Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?, Bone, 2007, 41, 3, 308

    CrossRef

  178. 178
    Paul D. Miller, Is There a Role for Bisphosphonates in Chronic Kidney Disease?, Seminars in Dialysis, 2007, 20, 3
  179. 179
    Audrey Gering, Laurent Grange, Céline Villier, Anne Woeller, Michel Mallaret, Les ostéonécroses de la mâchoire associées aux biphosphonates : synthèse bibliographique, Thérapie, 2007, 62, 1, 49

    CrossRef

  180. 180
    Jan J. Stepan, David B. Burr, Imre Pavo, Adrien Sipos, Dana Michalska, Jiliang Li, Astrid Fahrleitner-Pammer, Helmut Petto, Michael Westmore, David Michalsky, Masahiko Sato, Harald Dobnig, Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis, Bone, 2007, 41, 3, 378

    CrossRef

  181. 181
    Russell Garman, Glenn Gaudette, Leah-Rae Donahue, Clinton Rubin, Stefan Judex, Low-level accelerations applied in the absence of weight bearing can enhance trabecular bone formation, Journal of Orthopaedic Research, 2007, 25, 6
  182. 182
    Roland D Chapurlat, Monique Arlot, Brigitte Burt-Pichat, Pascale Chavassieux, Jean Paul Roux, Nathalie Portero-Muzy, Pierre D Delmas, Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study, Journal of Bone and Mineral Research, 2007, 22, 10
  183. 183
    Matthew R Allen, David B Burr, Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of bone, BoneKEy-Osteovision, 2007, 4, 2, 49

    CrossRef

  184. 184
    R.B. Martin, O.C. Yeh, D.P. Fyhrie, On sampling bones for microcracks, Bone, 2007, 40, 4, 1159

    CrossRef

  185. 185
    Melissa Mortensen, William Lawson, Andre Montazem, Osteonecrosis of the Jaw Associated With Bisphosphonate Use: Presentation of Seven Cases and Literature Review, The Laryngoscope, 2007, 117, 1
  186. 186
    Tim Van den Wyngaert, Manon T Huizing, Jan B Vermorken, Osteonecrosis of the jaw related to the use of bisphosphonates, Current Opinion in Oncology, 2007, 19, 4, 315

    CrossRef

  187. 187
    Kazuhiro Imai, Seizo Yamamoto, Yorito Anamizu, Toshiyuki Horiuchi, Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy, Journal of Bone and Mineral Metabolism, 2007, 25, 5, 333

    CrossRef

  188. 188
    Sumapa Chaiamnuay, Kenneth G. Saag, Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?, Reviews in Endocrine and Metabolic Disorders, 2007, 7, 1-2, 101

    CrossRef

  189. 189
    Matthew R Allen, David B Burr, Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of Treatment, Journal of Bone and Mineral Research, 2007, 22, 11
  190. 190
    E. Seeman, Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents, Osteoporosis International, 2007, 18, 5, 569

    CrossRef

  191. 191
    Sarah A. Galley, Donna J. Michalek, Seth W. Donahue, A fatigue microcrack alters fluid velocities in a computational model of interstitial fluid flow in cortical bone, Journal of Biomechanics, 2006, 39, 11, 2026

    CrossRef

  192. 192
    Yan Song, Gemunu H. Gunaratne, A method for vibrational assessment of cortical bone, Chaos: An Interdisciplinary Journal of Nonlinear Science, 2006, 16, 3, 033102

    CrossRef

  193. 193
    Matthew R. Allen, Ken Iwata, Roger Phipps, David B. Burr, Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate, Bone, 2006, 39, 4, 872

    CrossRef

  194. 194
    M. R. Allen, H. Follet, M. Khurana, M. Sato, D. B. Burr, Antiremodeling Agents Influence Osteoblast Activity Differently in Modeling and Remodeling Sites of Canine Rib, Calcified Tissue International, 2006, 79, 4, 255

    CrossRef

  195. 195
    Alexander G. Robling, Alesha B. Castillo, Charles H. Turner, BIOMECHANICAL AND MOLECULAR REGULATION OF BONE REMODELING, Annual Review of Biomedical Engineering, 2006, 8, 1, 455

    CrossRef

  196. 196
    Jean-Jacques Body, Bisphosphonates for malignancy-related bone disease: current status, future developments, Supportive Care in Cancer, 2006, 14, 5, 408

    CrossRef

  197. 197
    Ego Seeman, Pierre D. Delmas, Bone Quality — The Material and Structural Basis of Bone Strength and Fragility, New England Journal of Medicine, 2006, 354, 21, 2250

    CrossRef

  198. 198
    Meghan E. Ruppel, David B. Burr, Lisa M. Miller, Chemical makeup of microdamaged bone differs from undamaged bone, Bone, 2006, 39, 2, 318

    CrossRef

  199. 199
    Roland D Chapurlat, Pierre D Delmas, Drug Insight: bisphosphonates for postmenopausal osteoporosis, Nature Clinical Practice Endocrinology & Metabolism, 2006, 2, 4, 211

    CrossRef

  200. 200
    P. Díaz-Borrego, J. Pérez-Castilla, M. Álvarez-Sala, F. Sánchez-Doblado, Efectos biomecánicos de los campos electromagnéticos en el hueso en crecimiento de conejos, Rehabilitación, 2006, 40, 5, 235

    CrossRef

  201. 201
    Ian R. Reid, Emerging Issues With Bisphosphonates, Rheumatic Disease Clinics of North America, 2006, 32, 4, 691

    CrossRef

  202. 202
    I. Villamil Cajoto, M.J. Villacián Vicedo, C. Martínez Rey, Enfermedades metabólicas óseas: algo más que medicación, Revista Clínica Española, 2006, 206, 9, 465

    CrossRef

  203. 203
    Jeffrey G. Penfield, HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Multiple Myeloma in End-Stage Renal Disease, Seminars in Dialysis, 2006, 19, 4
  204. 204
    Solomon Epstein, Ibandronate treatment for osteoporosis: Rationale, preclinical and clinical development of extended dosing regimens, Current Osteoporosis Reports, 2006, 4, 1, 14

    CrossRef

  205. 205
    R.G.G. Russell, Ibandronate: Pharmacology and preclinical studies, Bone, 2006, 38, 4, S7

    CrossRef

  206. 206
    Alan W. Friedman, Important Determinants of Bone Strength, JCR: Journal of Clinical Rheumatology, 2006, 12, 2, 70

    CrossRef

  207. 207
    Vicente Gilsanz, Tishya AL Wren, Monique Sanchez, Frederick Dorey, Stefan Judex, Clinton Rubin, Low-Level, High-Frequency Mechanical Signals Enhance Musculoskeletal Development of Young Women With Low BMD, Journal of Bone and Mineral Research, 2006, 21, 9
  208. 208
    Kenneth J. Fischer, Thomas H.H. Vikoren, Susan Ney, Charles Kovach, Carl Hasselman, Mauli Agrawal, Harry Rubash, Arun S. Shanbhag, Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs, Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2006, 76B, 1
  209. 209
    Chao Yang Li, Karl J Jepsen, Robert J Majeska, Jian Zhang, Rujing Ni, Bruce D Gelb, Mitchell B Schaffler, Mice Lacking Cathepsin K Maintain Bone Remodeling but Develop Bone Fragility Despite High Bone Mass, Journal of Bone and Mineral Research, 2006, 21, 6
  210. 210
    S. Mohsin, F. J. O’Brien, T. C. Lee, Microcracks in compact bone: a three-dimensional view, Journal of Anatomy, 2006, 209, 1
  211. 211
    Matthew C. Farrugia, Don-John Summerlin, Edward Krowiak, Tod Huntley, Stephen Freeman, Richard Borrowdale, Charles Tomich, Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates, The Laryngoscope, 2006, 116, 1
  212. 212
    Jean-Yves Reginster, Jean-Pierre Devogelaer, Raloxifene Reduces Fractures in Postmenopausal Women with Osteoporosis, Clinical Orthopaedics and Related Research, 2006, 443, :, 48

    CrossRef

  213. 213
    E Michael Lewiecki, RANK ligand inhibition with denosumab for the management of osteoporosis, Expert Opinion on Biological Therapy, 2006, 6, 10, 1041

    CrossRef

  214. 214
    Kiichi Nonaka, Satoshi Fukuda, Kazuhiro Aoki, Takashi Yoshida, Keiichi Ohya, Regional distinctions in cortical bone mineral density measured by pQCT can predict alterations in material property at the tibial diaphysis of the Cynomolgus monkey, Bone, 2006, 38, 2, 265

    CrossRef

  215. 215
    W. Eugene Roberts, Bruce N. Epker, David B. Burr, James K. Hartsfield, Jeffery A. Roberts, Remodeling of Mineralized Tissues, Part II: Control and Pathophysiology, Seminars in Orthodontics, 2006, 12, 4, 238

    CrossRef

  216. 216
    M. Sosa Henríquez, Réplica, Revista Clínica Española, 2006, 206, 9, 466

    CrossRef

  217. 217
    K. Shawn Davison, Kerry Siminoski, J.D. Adachi, David A. Hanley, David Goltzman, Anthony B. Hodsman, Robert Josse, Stephanie Kaiser, Wojciech P. Olszynski, Alexandra Papaioannou, Louis-George Ste-Marie, David L. Kendler, Alan Tenenhouse, Jacques P. Brown, The Effects of Antifracture Therapies on the Components of Bone Strength: Assessment of Fracture Risk Today and in the Future, Seminars in Arthritis and Rheumatism, 2006, 36, 1, 10

    CrossRef

  218. 218
    Hongpu Zhao, Shangli Liu, Dongsheng Huang, Qiuyu Xu, Toshihide Shuto, Yukihide Iwamoto, The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis, Rheumatology International, 2006, 26, 8, 732

    CrossRef

  219. 219
    Jacqueline C. van der Linden, Jan H. Waarsing, Harrie Weinans, The use of micro-CT to study bone architecture dynamics noninvasively, Drug Discovery Today: Technologies, 2006, 3, 2, 213

    CrossRef

  220. 220
    J.-J. Body, Tumor bone disease, Annales d'Endocrinologie, 2006, 67, 2, 166

    CrossRef

  221. 221
    Miriam Delaney, Understanding Bone Strength, The Endocrinologist, 2006, 16, 2, 79

    CrossRef

  222. 222
    David W. Dempster, Hua Zhou, Dynamics of Bone and Cartilage Metabolism, 2006,

    CrossRef

  223. 223
    T. Mashiba, S. Hui, C.H. Turner, S. Mori, C.C. Johnston, D.B. Burr, Bone Remodeling at the Iliac Crest Can Predict the Changes in Remodeling Dynamics, Microdamage Accumulation, and Mechanical Properties in the Lumbar Vertebrae of Dogs, Calcified Tissue International, 2005, 77, 3, 180

    CrossRef

  224. 224
    Roland D Chapurlat, Clinical Pharmacology of Potent New Bisphosphonates for Postmenopausal Osteoporosis, Treatments in Endocrinology, 2005, 4, 2, 115

    CrossRef

  225. 225
    Neil Binkley, Diane Krueger, Combination therapy for osteoporosis: Considerations and controversy, Current Osteoporosis Reports, 2005, 3, 4, 150

    CrossRef

  226. 226
    Neil Binkley, Diane Krueger, Combination therapy for osteoporosis: Considerations and controversy, Current Rheumatology Reports, 2005, 7, 1, 61

    CrossRef

  227. 227
    Neil Binkley, Diane Krueger, Combination therapy for osteoporosis: Considerations and controversy, Current Osteoporosis Reports, 2005, 3, 4, 150

    CrossRef

  228. 228
    Neil Binkley, Diane Krueger, Current Osteoporosis Prevention and Management, Topics in Geriatric Rehabilitation, 2005, 21, 1, 17

    CrossRef

  229. 229
    Barbara M. Misof, Paul Roschger, Todd Baldini, Cathleen L. Raggio, Vivien Zraick, Leon Root, Adele L. Boskey, Klaus Klaushofer, Peter Fratzl, Nancy P. Camacho, Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse, Bone, 2005, 36, 1, 150

    CrossRef

  230. 230
    J. Mark Wilkinson, Alison C. Eagleton, Ian Stockley, Nicola F. A. Peel, Andrew J. Hamer, Richard Eastell, Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: A randomized trial, Journal of Orthopaedic Research, 2005, 23, 1
  231. 231
    Craig FJ Munns, Frank Rauch, Rose Travers, Francis H Glorieux, Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome, Journal of Bone and Mineral Research, 2005, 20, 7
  232. 232
    Craig D. Rubin, Emerging concepts in osteoporosis and bone strength, Current Medical Research and Opinion, 2005, 21, 7, 1049

    CrossRef

  233. 233
    Richard Eastell, Pierre D Delmas, How to Interpret Surrogate Markers of Efficacy in Osteoporosis, Journal of Bone and Mineral Research, 2005, 20, 7
  234. 234
    Chao Yang Li, Christopher Price, Kemesha Delisser, Philip Nasser, Damien Laudier, Mariza Clement, Karl J Jepsen, Mitchell B Schaffler, Long-Term Disuse Osteoporosis Seems Less Sensitive to Bisphosphonate Treatment Than Other Osteoporosis, Journal of Bone and Mineral Research, 2005, 20, 1, 117

    CrossRef

  235. 235
    Chao Yang Li, Christopher Price, Kemesha Delisser, Philip Nasser, Damien Laudier, Mariza Clement, Karl J Jepsen, Mitchell B Schaffler, Long-Term Disuse Osteoporosis Seems Less Sensitive to Bisphosphonate Treatment Than Other Osteoporosis, Journal of Bone and Mineral Research, 2005, 20, 1
  236. 236
    Jiliang Li, Masahiko Sato, Chris Jerome, Charles H. Turner, Zaifeng Fan, David B. Burr, Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene, Journal of Bone and Mineral Metabolism, 2005, 23, S1, 48

    CrossRef

  237. 237
    Robert R Recker, Janet Barger-Lux, Risedronate for prevention and treatment of osteoporosis in postmenopausal women, Expert Opinion on Pharmacotherapy, 2005, 6, 3, 465

    CrossRef

  238. 238
    Elise F. Morgan, John J. Lee, Tony M. Keaveny, Sensitivity of Multiple Damage Parameters to Compressive Overload in Cortical Bone, Journal of Biomechanical Engineering, 2005, 127, 4, 557

    CrossRef

  239. 239
    Satoshi Komatsubara, Satoshi Mori, Tasuku Mashiba, Jilliang Li, Kiichi Nonaka, Yoshio Kaji, Tomoyuki Akiyama, Kensaku Miyamoto, Yongping Cao, Jun Kawanishi, Hiromichi Norimatsu, Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib, Journal of Bone and Mineral Research, 2005, 20, 11
  240. 240
    T. Mashiba, S. Mori, S. Komatsubara, Y. Cao, T. Manabe, H. Norimatsu, D. B. Burr, THe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib, Journal of Bone and Mineral Metabolism, 2005, 23, S1, 36

    CrossRef

  241. 241
    Solomon Epstein, The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy, Mayo Clinic Proceedings, 2005, 80, 3, 379

    CrossRef

  242. 242
    Clifford J Rosen, Marc C Hochberg, Sydney L Bonnick, Michael McClung, Paul Miller, Susan Broy, Risa Kagan, Erluo Chen, Richard A Petruschke, Desmond E Thompson, Anne E de Papp, for the Fosamax Actonel Comparison Investigators, Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study, Journal of Bone and Mineral Research, 2005, 20, 1, 141

    CrossRef

  243. 243
    Clifford J Rosen, Marc C Hochberg, Sydney L Bonnick, Michael McClung, Paul Miller, Susan Broy, Risa Kagan, Erluo Chen, Richard A Petruschke, Desmond E Thompson, Anne E de Papp, Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study, Journal of Bone and Mineral Research, 2005, 20, 1
  244. 244
    Harald Dobnig, A review of teriparatide and its clinical efficacy in the treatment of osteoporosis, Expert Opinion on Pharmacotherapy, 2004, 5, 5, 1153

    CrossRef

  245. 245
    Jeffry S. Nyman, Oscar C. Yeh, Scott J. Hazelwood, R.Bruce Martin, A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage, Bone, 2004, 35, 1, 296

    CrossRef

  246. 246
    J. S. Day, M. Ding, P. Bednarz, J. C. van der Linden, T. Mashiba, T. Hirano, C. C. Johnston, D. B. Burr, I. Hvid, D. R. Sumner, H. Weinans, Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties, Journal of Orthopaedic Research, 2004, 22, 3
  247. 247
    Rowan J. Milner, James Farese, Carolyn J. Henry, Kim Selting, Timothy M. Fan, Louis-Philippe Lorimier, Bisphosphonates and Cancer, Journal of Veterinary Internal Medicine, 2004, 18, 5
  248. 248
    Gideon Rodan, Alfred Reszka, Ellis Golub, René Rizzoli, Bone safety of long-term bisphosphonate treatment, Current Medical Research and Opinion, 2004, 20, 8, 1291

    CrossRef

  249. 249
    Pierre D Delmas, Ego Seeman, Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy, Bone, 2004, 34, 4, 599

    CrossRef

  250. 250
    Marie-Paul Lecart, Olivier Bruyere, Jean-Yves Reginster, Combination/sequential therapy in osteoporosis, Current Osteoporosis Reports, 2004, 2, 4, 123

    CrossRef

  251. 251
    Marie-Paul Lecart, Olivier Bruyere, Jean-Yves Reginster, Combination/sequential therapy in osteoporosis, Current Osteoporosis Reports, 2004, 2, 4, 123

    CrossRef

  252. 252
    Margaret E Fadanelli, Henry G Bone, Combining Bisphosphonates with Hormone Therapy for Postmenopausal Osteoporosis, Treatments in Endocrinology, 2004, 3, 6, 361

    CrossRef

  253. 253
    O.S. Sobelman, J.C. Gibeling, S.M. Stover, S.J. Hazelwood, O.C. Yeh, D.R. Shelton, R.B. Martin, Do microcracks decrease or increase fatigue resistance in cortical bone?, Journal of Biomechanics, 2004, 37, 9, 1295

    CrossRef

  254. 254
    Ego Seeman, Estrogen, androgen, and the pathogenesis of bone fragility in women and men, Current Osteoporosis Reports, 2004, 2, 3, 90

    CrossRef

  255. 255
    Sarandeep S Huja, W.Eugene Roberts, Mechanism of osseointegration: characterization of supporting bone with indentation testing and backscattered imaging, Seminars in Orthodontics, 2004, 10, 2, 162

    CrossRef

  256. 256
    Frieder Bauss, Robert K. Schenk, Stefan Hört, Bernd Müller-Beckmann, Gisbert Sponer, New model for simulation of fracture repair in full-grown beagle dogs: Model characterization and results from a long-term study with ibandronate, Journal of Pharmacological and Toxicological Methods, 2004, 50, 1, 25

    CrossRef

  257. 257
    Matthew R. Allen, Janet M. Hock, David B. Burr, Periosteum: biology, regulation, and response to osteoporosis therapies, Bone, 2004, 35, 5, 1003

    CrossRef

  258. 258
    Faustino R. Pérez-López, Postmenopausal osteoporosis and alendronate, Maturitas, 2004, 48, 3, 179

    CrossRef

  259. 259
    Anthony I. Sebba, Sydney Lou Bonnick, Risa Kagan, Desmond E. Thompson, Carol S. Skalky, Erluo Chen, Anne E. de Papp, Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis, Current Medical Research and Opinion, 2004, 20, 12, 2031

    CrossRef

  260. 260
    Babul Borah, Thomas E Dufresne, Paula A Chmielewski, Troy D Johnson, Arkadi Chines, Michael D Manhart, Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography, Bone, 2004, 34, 4, 736

    CrossRef

  261. 261
    Satoshi Komatsubara, Satoshi Mori, Tasuku Mashiba, Jilliang Li, Kiichi Nonaka, Yoshio Kaji, Tomoyuki Akiyama, Kensaku Miyamoto, Yongping Cao, Jun Kawanishi, Hiromichi Norimatsu, Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib, Journal of Bone and Mineral Research, 2004, 19, 6
  262. 262
    H. Altundal, Ö. Güvener, The effect of alendronate on resorption of the alveolar bone following tooth extraction, International Journal of Oral and Maxillofacial Surgery, 2004, 33, 3, 286

    CrossRef

  263. 263
    Ronald A Lehman, Timothy R Kuklo, Brett A Freedman, Jerry R Cowart, Mark G Mense, K.Daniel Riew, The effect of alendronate sodium on spinal fusion: a rabbit model, The Spine Journal, 2004, 4, 1, 36

    CrossRef

  264. 264
    Nelson B Watts, Bisphosphonate treatment of osteoporosis, Clinics in Geriatric Medicine, 2003, 19, 2, 395

    CrossRef

  265. 265
    Stefan Judex, Steve Boyd, Yi-Xian Qin, Lisa Miller, Ralph Müller, Clinton Rubin, Combining high-resolution micro-computed tomography with material composition to define the quality of bone tissue, Current Osteoporosis Reports, 2003, 1, 1, 11

    CrossRef

  266. 266
    R. BRUCE MARTIN, Fatigue Damage, Remodeling, and the Minimization of Skeletal Weight, Journal of Theoretical Biology, 2003, 220, 2, 271

    CrossRef

  267. 267
    S.Y Smith, R.R Recker, M Hannan, R Müller, F Bauss, Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys, Bone, 2003, 32, 1, 45

    CrossRef

  268. 268
    Satoshi Komatsubara, Satoshi Mori, Tasuku Mashiba, Masako Ito, Jiliang Li, Yoshio Kaji, Tomoyuki Akiyama, Kensaku Miyamoto, Yongping Cao, Jun Kawanishi, Hiromichi Norimatsu, Long-Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog Vertebra, Journal of Bone and Mineral Research, 2003, 18, 3
  269. 269
    Aubrey Blumsohn, Roberta Faccio, Yebin Jiang, Gerard Karsenty, Robert F Klein, Mark A Kotowicz, Ian R Reid, Pamela G Robey, Ego Seeman, Gordon J Strewler, Meeting report from the 25th annual meeting of the American society for bone and mineral research, BoneKEy-Osteovision, 2003,

    CrossRef

  270. 270
    R Eastell, I Barton, Ra Hannon, A Chines, P Garnero, Pd Delmas, Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate, Journal of Bone and Mineral Research, 2003, 18, 6
  271. 271
    Bisphosphonates and Osteoporosis, New England Journal of Medicine, 2002, 346, 26, 2088

    CrossRef

  272. 272
    Susan M. Ott, Anna Oleksik, Yili Lu, Kristine Harper, Paul Lips, Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women, Journal of Bone and Mineral Research, 2002, 17, 2
  273. 273
    N.L Fazzalari, J.S Kuliwaba, M.R Forwood, Cancellous bone microdamage in the proximal femur: influence of age and osteoarthritis on damage morphology and regional distribution, Bone, 2002, 31, 6, 697

    CrossRef

  274. 274
    E.F Eriksen, F Melsen, E Sod, I Barton, A Chines, Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis, Bone, 2002, 31, 5, 620

    CrossRef

  275. 275
    J.H Hu, M Ding, K Søballe, J.E Bechtold, C.C Danielsen, J.S Day, I Hvid, Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone, Bone, 2002, 31, 5, 591

    CrossRef

  276. 276
    R.B Martin, Is all cortical bone remodeling initiated by microdamage?, Bone, 2002, 30, 1, 8

    CrossRef

  277. 277
    Juliet E Compston, Cyrus Cooper, John A Eisman, David J Hosking, Kassim Javaid, Paul D Miller, Gideon A Rodan, Ego Seeman, Meeting report from the IOF world congress on osteoporosis, BoneKEy-Osteovision, 2002,

    CrossRef

  278. 278
    Ego Seeman, Pathogenesis of bone fragility in women and men, The Lancet, 2002, 359, 9320, 1841

    CrossRef

  279. 279
    Ian R Reid, Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety, Expert Opinion on Drug Safety, 2002, 1, 1, 93

    CrossRef

  280. 280
    D.B. Burr, Targeted and nontargeted remodeling, Bone, 2002, 30, 1, 2

    CrossRef

  281. 281
    Stanley L.-S. Fan, John Cunningham, Bisphosphonates in renal osteodystrophy, Current Opinion in Nephrology and Hypertension, 2001, 10, 5, 581

    CrossRef

  282. 282
    Herbert Fleisch, Can Bisphosphonates Be Given to Patients with Fractures?, Journal of Bone and Mineral Research, 2001, 16, 3
  283. 283
    T Mashiba, C.H Turner, T Hirano, M.R Forwood, D.S Jacob, C.C Johnston, D.B Burr, Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures, Bone, 2001, 29, 3, 271

    CrossRef

  284. 284
    T Mashiba, D.B Burr, C.H Turner, M Sato, R.L Cain, J.M Hock, Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits, Bone, 2001, 28, 5, 538

    CrossRef

  285. 285
    T Mashiba, C.H Turner, T Hirano, M.R Forwood, C.C Johnston, D.B Burr, Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles, Bone, 2001, 28, 5, 524

    CrossRef

  286. 286
    Harold M. Frost, From Wolff's law to the Utah paradigm: Insights about bone physiology and its clinical applications, The Anatomical Record, 2001, 262, 4
  287. 287
    Ego Seeman, How do antiresorptive agents reduce fracture risk?, BoneKEy-Osteovision, 2001,

    CrossRef

  288. 288
    David B. Burr, Microdamage and bone fragility, Current Opinion in Orthopaedics, 2001, 12, 5, 365

    CrossRef

  289. 289
    Karen L. Bell, Nigel Loveridge, Jonathan Reeve, Christopher D.L. Thomas, Sophie A. Feik, John G. Clement, Super-osteons (remodeling clusters) in the cortex of the femoral shaft: Influence of age and gender, The Anatomical Record, 2001, 264, 4
  290. 290
    J. Tuukkanen, A. Koivukangas, T. Jämsä, K. Sundquist, C. A. MacKay, S. C. Marks, Mineral Density and Bone Strength Are Dissociated in Long Bones of Rat Osteopetrotic Mutations, Journal of Bone and Mineral Research, 2000, 15, 10
  291. 291
    S. Epstein, Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site, Aging Clinical and Experimental Research, 2000, 12, 5, 330

    CrossRef

  292. 292
    Mitchell Schaffler, Musculoskeletal Fatigue and Stress Fractures, 2000,

    CrossRef